Assessment of causal associations among gut microbes,plasma metabolites and idiopathic pulmonary fibrosis: a bidirectional Mendelian randomization study

Author:

Du Wei1,Wu Xiao wei1,Wu Jing1,Zhang Bing yu2,Chen Liang sheng1,Yi Xue1

Affiliation:

1. Institute of Respiratory research,Xiamen medical college

2. Public Health School of Fujian Medical University

Abstract

Abstract BACKGROUND: A collection of interstitial lung disorders, particularly in elderly individuals, with an uncertain cause is known as idiopathic pulmonary fibrosis. A growing body of research indicates that the causes of idiopathic pulmonary fibrosis may include the multifaceted interaction of gut microbes and plasma metabolites. However,uncertainty exists regarding the causative link between idiopathic pulmonary fibrosis, plasma metabolites, and gut microbes. METHODS:Based on GWAS database,two-sample MR analysis was used to identify gut microbes and plasma metabolites that influence the risk of developing idiopathic pulmonary fibrosis. Sensitivity analysis was used in order to assess the robustness of the results. At last, reverse MR was employed to explore reverse causation. RESULTS:The development of idiopathic pulmonary fibrosis may be influenced genetically by nine different gut microbes (family.Bacteroidaceae, genus.Bacteroides, genus.Senegalimassilia, etc.) and thirteen different plasma metabolites (glucose, 2-aminobutyrat, aspartylphenylalanine, etc.). Additionally, changes in 10 plasma metabolites and 9 gut microbes may result from idiopathic pulmonary fibrosis. CONCLUSION:We have established a causal association between gut microbes, plasma metabolites, and idiopathic pulmonary fibrosis for the first time with this research. Our research contributes to advancing both clinical therapies and public health strategies that will effectively reduce the incidence and social burden of IPF.

Publisher

Research Square Platform LLC

Reference43 articles.

1. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis;Wang J;Acta Pharm Sinica B,2022

2. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management;Luppi F;Respir Res,2021

3. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development;Spagnolo P;Pharmacol Ther,2021

4. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat;Maher TM;Respir Res,2019

5. Hamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H et al. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis. Disease markers 2016, 2016:4759040.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3